Guggenheim Maintains Buy on Zevra Therapeutics, Raises Price Target to $25
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
Guggenheim analyst Eddie Hickman maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Buy and raises the price target from $23 to $25.
Guggenheim analyst Eddie Hickman maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Buy and raises the price target from $23 to $25.